Atossa Therapeutics Inc
NASDAQ:ATOS
Intrinsic Value
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other... [ Read More ]
The intrinsic value of one ATOS stock under the Base Case scenario is 4.83 USD. Compared to the current market price of 1.49 USD, Atossa Therapeutics Inc is Undervalued by 69%.
Valuation Backtest
Atossa Therapeutics Inc
Run backtest to discover the historical profit from buying and selling ATOS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Atossa Therapeutics Inc
Current Assets | 92.2m |
Cash & Short-Term Investments | 88.5m |
Other Current Assets | 3.8m |
Non-Current Assets | 4m |
Long-Term Investments | 1.7m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 5.2m |
Accounts Payable | 806k |
Accrued Liabilities | 2.6m |
Other Current Liabilities | 1.8m |
Earnings Waterfall
Atossa Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-31.4m
USD
|
Operating Income
|
-31.4m
USD
|
Other Expenses
|
1.3m
USD
|
Net Income
|
-30.1m
USD
|
Free Cash Flow Analysis
Atossa Therapeutics Inc
What is Free Cash Flow?
ATOS Profitability Score
Profitability Due Diligence
Atossa Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Atossa Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ATOS Solvency Score
Solvency Due Diligence
Atossa Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Atossa Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATOS Price Targets Summary
Atossa Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ATOS is 4.67 USD with a low forecast of 4.04 USD and a high forecast of 6.04 USD.
Ownership
ATOS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ATOS Price
Atossa Therapeutics Inc
Average Annual Return | -19.37% |
Standard Deviation of Annual Returns | 69.17% |
Max Drawdown | -94% |
Market Capitalization | 186.7m USD |
Shares Outstanding | 125 304 000 |
Percentage of Shares Shorted | 8.43% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 4 full-time employees. The company went IPO on 2012-11-08. The firm is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. The company is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.
Contact
IPO
Employees
Officers
The intrinsic value of one ATOS stock under the Base Case scenario is 4.83 USD.
Compared to the current market price of 1.49 USD, Atossa Therapeutics Inc is Undervalued by 69%.